Abstract
Systemic Therapy for Metastatic Non-Clear Cell Renal Carcinoma
Highlights
Renal cell carcinoma (RCC) accounts for 2–3% of all malignant diseases in adults
There are some evidences supporting the use of these agents in patients with non-clear cell RCCs, additional prospective trials with these agents are needed to further clarify their use in these histologic subtypes
Efficacy and safety of temsirolimus was demonstrated in a multicenter, randomized, open-label phase III trial (Global Advanced Renal Cell Carcinoma [ARCC] trial) in previously untreated patients with advanced RCC who had at least 3 unfavorable prognostic factors [31]
Summary
Canc Therapy & Oncol Int J Copyright © All rights are reserved by Parham Khosravi-Shahi. Antiangiogenic agents (sorafenib, sunitinib, pazopanib, temsirolimus, or bevacizumab), have not been evaluated in phase III trials in patients with nonclear cell tumors. Their efficacy is unclear in the treatment of non-clear cell renal carcinomas. In a subset analysis of a randomized phase III trial, patients with non-clear cell and clear cell advanced RCCs, treated with temsirolimus, demonstrated comparable median overall and progression-free survival. Patients with metastatic papillary and chromophobe RCCs may have prolonged progression-free survival from sunitinib and sorafenib, clinical responses remain overall low. This review article focuses on all these options for non-clear cell advanced RCC
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Cancer therapy & Oncology International Journal
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
